BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 30144151)

  • 1. Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    How J; Vij KR; Ebadi M; DeFor TE; Romee R; Dolan MM; Ustun C; Weisdorf DJ; Linden MA; Rashidi A
    Am J Hematol; 2018 Dec; 93(12):E381-E383. PubMed ID: 30144151
    [No Abstract]   [Full Text] [Related]  

  • 2. History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease-negative first complete remission.
    Rashidi A; Linden MA; DeFor TE; Warlick E; Bejanyan N; Yohe S; Weisdorf DJ; Ustun C
    Am J Hematol; 2017 Oct; 92(10):1032-1036. PubMed ID: 28646534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia.
    Venditti A; Piciocchi A; Candoni A; Melillo L; Calafiore V; Cairoli R; de Fabritiis P; Storti G; Salutari P; Lanza F; Martinelli G; Luppi M; Mazza P; Martelli MP; Cuneo A; Albano F; Fabbiano F; Tafuri A; Chierichini A; Tieghi A; Fracchiolla NS; Capelli D; Foà R; Alati C; La Sala E; Fazi P; Vignetti M; Maurillo L; Buccisano F; Del Principe MI; Irno-Consalvo M; Ottone T; Lavorgna S; Voso MT; Lo-Coco F; Arcese W; Amadori S
    Blood; 2019 Sep; 134(12):935-945. PubMed ID: 31395600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consolidation chemotherapy prior to hematopoietic cell transplantation for adults with acute myeloid leukemia in first remission.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2016 Dec; 29(4):365-371. PubMed ID: 27890261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When should patients receive consolidation chemotherapy before allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission?
    Yeshurun M; Wolach O
    Curr Opin Hematol; 2018 Mar; 25(2):75-80. PubMed ID: 29283907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Consolidation Cycles Before Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission.
    Lee YJ; Baek DW; Ahn JS; Ahn SY; Jung SH; Yang DH; Lee JJ; Kim HJ; Ham JY; Suh JS; Sohn SK; Moon JH
    Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):e529-e535. PubMed ID: 30268640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis.
    Limvorapitak W; Barnett MJ; Hogge DE; Forrest DL; Nevill TJ; Narayanan S; Power MM; Nantel SH; Broady R; Song KW; Toze CL; Mourad YA; Sutherland HJ; Gerrie AS; White J; Sanford DS
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e481-e491. PubMed ID: 30100330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Yeshurun M; Labopin M; Blaise D; Cornelissen JJ; Sengeloev H; Vindelov L; Kuball J; Chevallier P; Craddock C; Socie G; Bilger K; Schouten HC; Fegueux N; Goker H; Maertens J; Bunjes D; Arnold R; Nagler A; Mohty M
    Cancer; 2014 Mar; 120(6):855-63. PubMed ID: 24338939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation.
    Jentzsch M; Grimm J; Bill M; Brauer D; Backhaus D; Schulz J; Goldmann K; Niederwieser D; Platzbecker U; Schwind S
    Blood Cancer J; 2021 Apr; 11(4):80. PubMed ID: 33927190
    [No Abstract]   [Full Text] [Related]  

  • 11. Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Li WY; Wang Y; Chen SN; Qiu HY; Fu ZZ; Wu DP; Sun AN
    Leuk Lymphoma; 2018 Jul; 59(7):1652-1658. PubMed ID: 29043875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of minimal residual disease prior to unmanipulated haploidentical hematopoietic stem cell transplantation in patients with acute myeloid leukemia in complete remission.
    Zhao XS; Qin YZ; Liu YR; Chang YJ; Xu LP; Zhang XH; Huang XJ
    Leuk Lymphoma; 2017 May; 58(5):1135-1143. PubMed ID: 27733089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
    Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
    Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.
    Rohatiner AZ; Smith ML; Spinelli O; Rambaldi A; Bassan R; di Bona E; Rodeghiero F; Raimondi R; Björkholm M; Johnson S; Newland AC; Cavenagh JD; Macdougall F; Waters R; Fitzgibbon J; Barbui T; Lister A
    Br J Haematol; 2014 Dec; 167(5):724-6. PubMed ID: 25074579
    [No Abstract]   [Full Text] [Related]  

  • 16. Hematopoietic cell transplantation as treatment of patients with acute myeloid leukemia with measurable residual disease after consolidation therapy.
    Appelbaum FR
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):405-409. PubMed ID: 30466757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?
    Buccisano F; Walter RB
    Curr Opin Hematol; 2017 Mar; 24(2):132-138. PubMed ID: 27930388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of adult patients with acute myeloid leukemia (excluding acute promyelocytic leukemia)].
    Usui N
    Rinsho Ketsueki; 2014 Oct; 55(10):1808-16. PubMed ID: 25297744
    [No Abstract]   [Full Text] [Related]  

  • 20. Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia.
    Oran B; Jorgensen JL; Marin D; Wang S; Ahmed S; Alousi AM; Andersson BS; Bashir Q; Bassett R; Lyons G; Chen J; Rezvani K; Popat U; Kebriaei P; Patel K; Rondon G; Shpall EJ; Champlin RE
    Haematologica; 2017 Jan; 102(1):110-117. PubMed ID: 27540139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.